Walleye Trading’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Walleye Trading’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,425	Closed	-$142K	–	5634
2023 Q4	$142K	Buy	2,425 +1,726	+247%	+$97K	﹤0.01%	3979
2023 Q3	$30.4K	Buy	+699	New	+$25K	﹤0.01%	4316
2023 Q2	–	Sell	-14,645	Closed	-$603K	–	5338
2023 Q1	$545K	Buy	+14,645	New	+$659K	﹤0.01%	2730
2021 Q1	–	Sell	-117	Closed	-$26K	–	5445
2020 Q4	$26K	Buy	+117	New	+$25.3K	﹤0.01%	4344
2020 Q1	–	Sell	-8,457	Closed	-$758K	–	4723
2019 Q4	$1.09M	Buy	+8,457	New	+$816K	0.01%	1727
2018 Q3	–	Sell	-6,155	Closed	-$303K	–	5624
2018 Q2	$303K	Buy	+6,155	New	+$232K	﹤0.01%	3285
2016 Q4	–	Sell	-3,600	Closed	-$24K	–	5307
2016 Q3	$24K	Buy	+3,600	New	+$19.2K	﹤0.01%	4118

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Walleye Trading's MRTX Position: Q1 2024 in Review

Walleye Trading sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 2,425 shares — an estimated $142K sold.

Walleye Trading first reported a position in MRTX in Q3 2016 and held it in 7 quarters. The position peaked at $1.09M in Q4 2019. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

Walleye Trading reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Walleye Trading sold 2,425 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $142K.
Walleye Trading first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2016 and held it in 7 quarters.
Walleye Trading's Mirati Therapeutics, Inc. Common Stock position peaked at $1.09M in Q4 2019.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Walleye Trading's 13F filing for Q1 2024, filed 15 May 2024.